Review Article
Split Viewer
Blood Res 2023; 58(S1):
Published online April 30, 2023
https://doi.org/10.5045/br.2023.2023015
© The Korean Society of Hematology
Practical issues in CAR T-cell therapy
Correspondence to : Ja Min Byun, M.D.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: jaminbyun@naver.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.
Keywords CAR T-cell therapy, Korea, Patient access, Barrier
PDF
Standard view
Export citation
Share Article
Review Article
Blood Res 2023; 58(S1): S11-S12
Published online April 30, 2023 https://doi.org/10.5045/br.2023.2023015
Copyright © The Korean Society of Hematology.
Practical issues in CAR T-cell therapy
Ja Min Byun
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea
Correspondence to:Ja Min Byun, M.D.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
E-mail: jaminbyun@naver.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.
Keywords: CAR T-cell therapy, Korea, Patient access, Barrier
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
Clinical Analysis of Hospitalized Patients with Hemophilia A: Single-hemophilia Treatment Center Experience in Korea over 10 years
Ju Young Kim, Se Jin Park, Chur Woo You
Blood Res 2021; 56(3): 141-149 -
Reference values for serum ferritin and percentage of transferrin saturation in Korean children and adolescents
Hea Lin Oh, Jun Ah Lee, Dong Ho Kim, and Jung Sub Lim
Blood Res 2018; 53(1): 18-24 -
Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma
Hyun-Young Kim, Mi-Ae Jang, Hee-Jin Kim, Seok Jin Kim, Won Seog Kim, and Sun-Hee Kim
Blood Res 2017; 52(3): 193-199
